Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
First received: September 25, 2007
Last updated: July 12, 2012
Last verified: July 2012
In a prospective and randomized study protocol, three different blood pressure regulating agents (nitroprusside, nitroglycerine, sevoflurane) will be compared concerning their effect on the cerebral oxygen balance between both hemispheres during aortic coarctation repair. Cerebral and somatic saturation will be monitored non-invasively and continuously via optical sensors applied to the right and left forehead and the somatic regions. Arterial blood pressure, central venous pressure, heart rate and systemic saturation will be recorded continuously. Intermittently, arterial and venous blood gas analysis will be performed at 6 definite time intervals. The study ends at the end of the operation.

Condition Intervention Phase
Cerebral Oxygenation
Drug: nitroprusside
Drug: nitroglycerine
Drug: sevoflurane
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: a Randomized Study

Resource links provided by NLM:

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Cerebral saturation [ Time Frame: During operation ] [ Designated as safety issue: Yes ]

Enrollment: 30
Study Start Date: October 2007
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Administration of nitroprusside
Drug: nitroprusside
Administration of nitroprusside
Experimental: 2
Administration of nitroglycerine
Drug: nitroglycerine
Administration of nitroglycerine
Experimental: 3
Administration of sevoflurane
Drug: sevoflurane
Administration of Sevoflurane


Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All neonates and infants
  • Aged 0-18 year
  • With aortic coarctation requiring surgical correction without the additional use of cardiopulmonary bypass will be included.

Exclusion Criteria:

  • All patients with an associated cardiac effect are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00535808

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Principal Investigator: Annelies Moerman, MD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT00535808     History of Changes
Other Study ID Numbers: 2007/270 
Study First Received: September 25, 2007
Last Updated: July 12, 2012
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Additional relevant MeSH terms:
Aortic Coarctation
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Heart Defects, Congenital
Heart Diseases
Anesthetics, General
Anesthetics, Inhalation
Antihypertensive Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Nitric Oxide Donors
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on April 27, 2016